Senzime AB ( (SNZZF) ) has released its Q1 earnings. Here is a breakdown of the information Senzime AB presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Senzime AB is a global medical technology company specializing in algorithm-driven patient monitoring systems aimed at reducing anesthesia-related complications, with operations in over 40 markets and partnerships with leading academic institutions.
In its first quarter of 2025, Senzime reported a 94% increase in net sales compared to the same period last year, driven by strong demand for its next-generation TetraGraph systems and disposable sensors, particularly in the USA.
Key financial highlights include a significant increase in sales of disposable sensors by 97%, a gross margin improvement to 65.9%, and the successful launch of TetraGraph integration with Masimo Iris Gateway. The company also secured several new hospital contracts in the US, contributing to its robust sales performance. Despite these achievements, the company reported a loss after financial items of SEK -35,522 thousand, reflecting ongoing investments in expansion and innovation.
Looking ahead, Senzime’s management remains optimistic about continued growth, supported by strong demand and strategic partnerships. The company plans further expansions and product launches in Japan and South Korea, while also exploring local production opportunities in the US to mitigate potential impacts from new tariffs.